To evaluate the predictive capability of circular RNAs (circRNAs) in blood for imminent Alzheimer’s disease (AD) symptoms compared to traditional biomarkers.
Approach:
Study Design: Analyzed blood data from over 1,200 individuals across multiple cohorts to identify circRNAs associated with AD.
Biomarker Comparison: Compared predictive models based on circRNAs with those based on pTau217, the leading clinical blood-based biomarker for AD.
Key Findings:
Elevated levels of specific circRNAs nearly tripled the risk of developing AD symptoms.
The circRNA model outperformed the pTau217 model in predicting progression to symptomatic AD.
CircRNA levels diverged from normal approximately two to four years prior to symptom onset.
Interpretation:
Limitations:
The study's findings need to be validated in larger, diverse populations.
Further research is required to develop clinical assays for circRNAs.
Conclusion:
The research lays the groundwork for potential blood tests that could predict AD symptom onset and monitor treatment responses.
